Phase ii and pharmacodynamic study of autophagy inhibition using hydroxychloroquine in patients with metastatic pancreatic adenocarcinoma

Oncologist

Volumn 19, Issue 6, 2014, Pages 637-638

  Wolpin, Brian M ^a,b   Rubinson, Douglas A ^a,b   uwang, Xiaoxu ^a,b   Chan, Jennifer A ^a,b   Cleary, James M ^a,b   Enzinger, Peter C ^a,b   Fuchs, Charles S ^a,b   Mccleary, Nadine J ^a,b   Meyerhardt, Jeffrey A ^a,b   Kimmie, N G ^a,b   Schrag, Deborah ^a,b   Sikora, Allison L ^a,b   Spicer, Beverly A ^a,b   Killion, Leah ^a,b   Mamon, Harvey ^a,b   Kimmelman, Alec C ^a,b  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; BETA ACTIN; HYDROXYCHLOROQUINE; PROTEIN P62; ANTINEOPLASTIC AGENT; MAP1LC3 PROTEIN, MOUSE; MICROTUBULE ASSOCIATED PROTEIN;

ANIMAL CELL; ARTICLE; AUTOPHAGY; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG TOLERABILITY; HUMAN; HUMAN CELL; LYMPHOCYTOPENIA; MOUSE; NONHUMAN; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PERIPHERAL LYMPHOCYTE; PHARMACODYNAMICS; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; TUMOR GROWTH; TUMOR REGRESSION; WESTERN BLOTTING; ADENOCARCINOMA; ANIMAL; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DRUG EFFECTS; GENETICS; LYMPHOCYTE; METABOLISM; METASTASIS; PANCREATIC NEOPLASMS; PATHOLOGY;

ADENOCARCINOMA; ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AUTOPHAGY; DISEASE-FREE SURVIVAL; HUMANS; HYDROXYCHLOROQUINE; LYMPHOCYTES; MICE; MICROTUBULE-ASSOCIATED PROTEINS; NEOPLASM METASTASIS; PANCREATIC NEOPLASMS;

EID: 84901933891     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2014-0086     Document Type: Article

References (0)